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Abstract 
 
 
The VP3 (Apoptin) protein from the Chicken Anemia Virus has been shown to selectively kill 
transformed cells; an activity that is dependent on subcellular localization. Studies note that Apoptin 
forms large multimers during this process and the role of this aggregation in cell type-specific 
apoptosis is unclear. Previous studies indicate that the nuclear export and multimerization activities 
occur via the same domain, however all current mutations affecting export also interfere with 
multimerization. Here we show that introduction of a point mutant (I37A) in the nuclear export 
sequence of Apoptin uncouples multimerization and nuclear export activities. Separation of these 
activities should elucidate the role of multimerization in cell type-specific apoptosis.  
1 
Introduction 
 
Viral Replication 
 Many viruses manipulate the host cell cycle to replicate in the cell and propogate 
infection.  The cell cycle is controlled by a series of proteins that regulate each stage of cell 
division. The major regulators are the cyclins, a family of proteins named for their oscillatory 
concentrations during cell cycle progression.  Cyclins complex with and activate the protein 
kinase function of cyclin-dependent kinases (Cdk). These complexes are regulated via Cdk-
activating kinases and Cdk inhibitors.  Combinations of different cyclin and Cdk proteins lead to 
the activation of different stages in the cell cycle.[20] Manipulation of the cell cycle is possible 
through a variety of viral regulatory proteins that interact and interface with cyclins and/or Cdks 
(directly or indirectly). For example, small DNA viruses have been found to drive the cell into S 
phase by inactivating pRb. The retinoblastoma family of proteins regulates the cell cycle at S 
phase by binding and inhibiting transcription factors in the E2F family, namely E2F-1, which 
activate genes involved in S-phase such as cdt1+ (an initiation factor) and hsk1+ (a protein 
kinase).  This allows the virus to make use of the host’s DNA replication processes for the 
proliferation of the viral genome. Another example is the Epstein-Barr virus (EBV), which 
causes multiple forms of lymphoma (cancer in lymphocytes) and carcinoma (cancer in epithelial 
cells), through expression of a protein, EBNA-3C, that also binds and inhibits Rb. [21] [4] 
Host cell cycle manipulation by viral proteins can also occur through repression of p53. 
p53 is responsible for two major cellular functions, initiation of apoptosis and/or cessation of the 
cell cycle via G1 arrest. In this process p53 (which serves as a transcription factor) upregulates 
transcription of the p21 protein, which inhibits the kinase complexes required for G1/S transition, 
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terminating the cell cycle.  Over half of all human cancers have a mutated p53 gene and many 
repress p53 activity. Inactivation of p53 allows the virus to continue proliferation because cell 
function cannot be halted through p53-mediated arrest or apoptosis. [4] Thus, many viruses 
attempt to either inhibit p53 production or p53 activity to allow for unregulated growth and 
increased S-phase induction. Several instances of such viral interference with p53 have been 
studied.  For example, the Epstein-Barr virus (EBV) activates the A20 gene which inhibits the 
mediation of apoptosis by p53.[2]  Several instances of viral interaction with p53 have been 
studied, such as that of Simian virus 40 (SV40).  At the onset of infection, SV40 transforms the 
host cell by expressing the large and small T antigens, which bind to p53 and inactivate it.  The 
cell then enters a cycle of unmonitored proliferation for SV40.[1]  Some viruses encode proteins 
that interfere with the activity of p53 and Rb, while others encode proteins that stimulate 
apoptosis.[1][8] 
 
Virus-induced apoptosis 
Animal viruses can also encode proteins that stimulate apoptosis, or programmed cell 
death. Apoptosis is typified through cell shrinkage, partitioning of the nucleus, cleavage and 
degradation of DNA, and phagocytosis by surrounding cells.[12]  Apoptotic activity that results 
from these proteins may allow the virus to spread throughout the host, however this phenomenon 
remains unclear.  
Two major pathways for the activation of caspases, a family of cysteine proteases which 
are used in cell dismantling, have been discerned.  The intrinsic pathway occurs in mitochondria 
in a process by which cytochrome c within the mitochondrial membrane is released into the 
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cytosol.  Cytochrome c then binds Apf1, a caspase-activating protein, which subsequently forms 
a caspase-activating complex (which includes cytochrome c, Apf1, and initiator caspases) that 
triggers the initiation of the caspase activation cascade.[2][23]  Intrinsic apoptosis is hindered by 
Bcl-2 and some related family members, which are located on the outer mitochondrial membrane 
and downstream from caspase 3. Bcl-2 is the mammalian correspondent of regulatory genes 
initially discovered in C. elegans and is part of a complex family of proteins that have both pro- 
and anti-apoptotic functionality.  This protein was found to avert apoptosis by preventing the 
release of cytochrome c within the mitochondria.  These experiments also showed that 
cytochrome c release precedes other early apoptotic events such as mitochondrial membrane 
depolarization.[27] 
Extrinsic apoptosis is dependent on the tumor necrosis factor (TNF) superfamily of 
receptors.  Upon ligand binding, the receptor’s intracellular death domain clusters and proceeds 
to form the death-inducing signaling complex (DISC).  DISC formation is followed closely by 
initiator caspase activation and ultimately apoptosis.  It has been argued that intrinsic and 
extrinsic pathways are capable of interaction. Caspase-8, an initiator activated in the extrinsic 
pathway, has been shown to cleave a pro-apoptotic member of the Bcl-2 family, Bid.  Entry of 
cleaved Bid into mitochondria results in cytochrome-c release into the cytosol, triggering 
activation of the intrinsic pathway.[19][26] 
 Caspases are activated through these pathways and serve major roles in apoptosis.  
Enzymatic degradation is an irreversible process that results in cell death, thus few approaches 
exist for controlling caspase activity.  All identified caspases have a similar structure:  an N-
terminal prodomain (which is cleaved for activation), a large 20 kDa subunit and a small 10 kDa 
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subunit.  The caspases also exhibit substrate specificity.[2][23] Caspase-mediated apoptosis 
includes inactivation of proteins, through degradation, that safeguard the cell from apoptotic 
changes.  Caspases activate through a cascade that is initiated by acute specificity for aspartic 
acid.  Each caspase has an aspartic acid cleavage site that allows for activation of caspases 
further along the cascade.  These are broadly divided into two groups: initiation and effector 
caspases.  Effector caspases then inactivate the aforementioned regulatory proteins.[2][23]   
Some viruses are apoptotic and more specifically, others are cancer-killing viruses.   A 
select number of viruses have been found to induce apoptosis, a subset of which induces 
apoptosis in a transformation-specific manner such as adenovirus type 5.   Additionally, some 
viruses encode a single protein capable of selectively inducing apoptosis in cancer cells. An 
example is viral protein 3 of the chicken anemia virus.  
 
The Chicken Anemia Virus (CAV) 
 CAV, a virus of the family Circoviridae and the genus Gyroviridae, was discovered 
during an investigation of a Marek’s disease outbreak.  Marek’s disease is a highly contagious 
virus in chickens. The isolates from this study were originally designated a chicken anemia agent 
(CAA) found in commercially produced chickens [28] however further studies indicated that 
CAA biochemically resembled the porcine circovirus, and CAA was therein denoted CAV.  The 
virus itself is small in size (the genome is approximately 2,300 nucleotides) and is composed of 
circular single-stranded DNA.[25] 
CAV infects chickens shortly after hatching.  Within 14 days of infection the virus 
induces anemia (deficiency in red blood cells) and leads to secondary infections.[7]  Physical 
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symptoms observed 16 days after inoculation with CAV include degradation of bone marrow 
(yellow color), bone marrow lesions, shrunken thymus, swollen and discolored liver, 
hemorrhaged skeletal muscle, and hemorrhaged mucosal membrane.  Depression and anorexia 
are also associated symptoms.  Chickens exhibiting the worst symptoms die between two and 
four weeks of age.[28] 
 The CAV genome encodes three viral proteins (VP1, VP2, and VP3) in three overlapping 
open reading frames, all of which are required for viral replication. Few discoveries have been 
made about the functions of VP1 of ORF3 (52kDa; the only CAV capsid protein) and VP2 of 
ORF1 (24 kDa; significant in CAV replication and influences virulence) to date.[25]  Koch et. al. 
[8] have proven that VP2 is necessary for CAV assembly and Peters et. al. [17] have shown that 
VP2 is a protein-tyrosine phosphatase (PTPase) after discovering a remarkable homology 
between the sequence of VP2 and other dual-specificity phosphatases.[16]  Dual specificity 
phosphatases are characterized by their ability to remove phosphate groups from 
phosphotyrosine and phosphothreonine residues via cysteine and arginine residues in the 
catalytic motif (which are highly conserved among PTPases), both of which were observed in 
kinetic studies of VP2.  VP2 is expressed at nearly undetectable levels at the onset of infection, 
an attribute of regulatory proteins necessary for viral replication that serve a non-structural 
role.[17] 
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Fig. 1 CAV genome.  A schematic representation of the CAV genome.  The CAV genome 
transcribes a single mRNA with multiple translational start sites for the three CAV proteins:  
VP1, VP2 and VP3. 
 
 
CAV VP3:  Apoptin 
 VP3, herein referred to as Apoptin, consists of 121 amino acids with two proline-packed 
stretches and two basic regions.[29]  Much like VP2, Apoptin is a non-structural protein that 
shortly after infection is distributed in a dispersed granular pattern within the cell however 
Apoptin later accumulates in proximity to isolated apoptotic structures.  Bcl-2, which was found 
to generally inhibit intrinsic apoptosis via pathways such as p53, can inhibit Apoptin-mediated 
apoptosis, indicating that Apoptin-mediated apoptosis follows a mitochondrial intrinsic 
pathway.[11]  In order to effectively induce apoptosis, Apoptin must have proper subcellular 
localization to the nucleus. Once nuclear localization occurs, Apoptin can bind and inhibit the 
target of apoptotic interaction. 
This target is the Anaphase Promoting Complex (APC/C).  The APC/C is a vital protein 
for cell cycle regulation.  The APC/C is a complex protein with thirteen core subunits and two 
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associated subunits, Cdc20 and Cdh1.[24]  The two associated subunits are responsible for the 
two assemblies of APC/C:  APC/C
Cdc20
 and APC/C
Cdh1
.[15]  APC/C
Cdc20
 is important for mitotic 
regulation.  APC/C is the enzyme responsible for the regulation of the cyclins, proteins that are 
responsible to initiating the various stages of mitosis, through ubiquitin-dependent proteolysis. 
[15]  In addition to APC/C's role in cyclin proteolysis, the complex is responsible for activating 
separase.  This cleavage is the initiation of anaphase.[16]  Interference with this essential 
regulatory protein can severely affect the cell cycle. 
 Apoptin has been found to inhibit the anaphase promoting complex/cyclosome, leading to 
G2/M arrest and eventually apoptosis in transformed cells.[6]  Apoptin binds to APC1.  APC1 is 
the largest subunit in the complex and performs a scaffolding function.  It has been proposed that 
the APC/C is destabilized when Apoptin binds to this subunit.[5]  It was shown that Apoptin 
binding produces complexes that were significantly smaller in molecular weight than a full 
APC/C complex and some were the size of a single subunit, indicating destabilization of the 
APC/C. [22]     
 This destabilization of a crucial cell cycle regulatory complex leads to mitochondrial 
apoptosis through the Nur77 pathway, a p53-independent pathway.[10][5]  The p53 pathway 
serves as a primary avenue for apoptosis of cancer cells by chemotherapy.  However, this 
pathway is mutated in nearly half of naturally occurring tumors.  Therefore, a p53-independent 
pathway for induced cell death is an important finding for future cancer research. 
 Studies have shown that in transformed cells, Apoptin is located primarily in the nucleus, 
while for normal cells Apoptin is located primarily in the cytoplasm.[13][6]  In primary cells, 
Apoptin formed a pattern similar to cytoskeletal structures, suggesting that Apoptin may be 
8 
aggregating and complexing with the cytoskeleton or forming a filament itself. [22]   In the 
nucleus of transformed cells, Apoptin binds to APC/C, however Apoptin does not bind to the 
APC/C in primary cells.  It has been concluded that the presence of Apoptin in the nucleus of 
transformed cells is necessary for the selective apoptotic effect. [21] 
 
Nuclear Import and Export of Apoptin 
 Major transport into and out of the nucleus is mediated by proteins called karyopherins 
and membrane proteins called nucleoporins.  Karyopherins tag proteins in the cytoplasm and 
nucleoplasm for import and export.  An adapter protein is often used to bind the protein to be 
transported, which in turn is bound to the karyopherins.  Either the karyopherin or adapter 
protein binds to key amino acid residues on the protein.  Subsequent protein conformation of the 
karyopherin allows it to be recognized by the nucleoporin and bound.  Once bound, the entire 
complex is transported across the membrane through the nucleoporin.  For import, the importin-α 
family of karyopherins is often used as an adapter protein while the importin-β family of 
karyopherins can bind importin-α or act independently.  Nuclear export is usually handled by the 
binding of the karyopherin Crm1.[14] 
  
The nuclear localization sequences (NLS) of proteins have been difficult to define.  There 
has yet to be a conserved sequence to identify the NLS.[13]  In contrast,  nuclear export 
sequences (NES) have a loosely conserved sequence of hydrophobic residues, mostly leucine 
and isoleucine.[3]  The karyopherin Crm1 is responsible for interaction with the NES.[8][38]  
This karyopherin makes use of the Ran-GTP cycle.  Ran complexes with the protein to be 
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exported by recognizing and binding the nuclear export sequence found on the protein.[14]  
Crm1 recognizes Ran-GTP and exports the cargo across the nuclear membrane.  Once exported, 
Crm1 dephosphorylates Ran-GTP to Ran-GDP and the substrate to be transported is dissociated. 
 Apoptin undergoes nucleocytoplasmic shuttling through the functions of its nuclear 
export and nuclear import sequences.[6]  It has been shown to be exported from the nucleus by 
Crm1 and imported by importin-β1.[18][6]  This indicates that Apoptin uses existing cellular 
mechanisms to move between the nucleus and cytoplasm.  To prove that Apoptin is transported 
out of the nucleus, nuclear export was blocked by leptomycin B.  This resulted in the nuclear 
accumulation of Apoptin in primary cells.[6]  To prove that Apoptin is transported into the 
nucleus, Ran dependent nuclear import was blocked with a dominant-negative Ran GTPase 
mutant.  This resulted in the ctyoplasmic accumulation of Apoptin.[6]  In addition, both 
import/export sequences are active at the same time, resulting in an equilibrium in protein 
shuttling.  This shuttling has been shown to be critical to the cell-type specific apoptosis induced 
by Apoptin, however the exact role is unknown.  Removal of either the nuclear export sequence 
or the nuclear import sequence results in a loss of cell type-specific localization.[6] 
  Studies have shown that introducing a generic nuclear localization sequence does not 
affect Apoptin's ability to selectively induce apoptosis.  Apoptin's NLS can be replaced with a 
heterologous sequence, SV40 large T-antigen with no detected change in the cell-type specific 
localization of Apoptin.[6]  This indicates that it may be the nuclear export sequence that is the 
key to the cell type selectivity.  The NES of Apoptin, a leucine-rich region between amino acids 
33 and 46 (IRIGIAGITITLSL), was replaced with an established NES, such as that of the Rev 
protein, results in a similar localization pattern for both transformed and primary cell types.  
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Interestingly, in all cases where export is lost, the same cytoplasmic filamentous pattern was not 
produced.[6]   
 
Apoptin:  Multimerization 
 Studies indicate that an unspecified domain is responsible for Apoptin multimerizing with 
itself.[6][10]  Data indicates that Apoptin multimerizes with itself in both transformed and 
primary cells.  However, the extent of multimerization differs between cell types.  In normal cells 
Apoptin forms mostly large, insoluble complexes in the cytosol.  In transformed cells Apoptin is 
mostly soluble (unpublished data, D.W. Heilman).  When it does multimerize in transformed 
cells, it interacts with Promyelocytic Leukemia (PML) bodies in the nucleus, which contain 
APC/C.[9]  Multimerization may be critical for this localization and for the induction of 
apoptosis. [29] 
 Studies in which N-terminal residues were mutated in Apoptin resulted in elimination of 
aggregate formation [9], the ability to induce apoptosis, and loss of cell type selectivity [6].  The 
marked reduction in multimerization from the replacement of the NES indicates that Apoptin's 
NES contains important amino acid residues required for effective multimerization.[6]  In an 
effort to determine the role of multimerization and nuclear export activities in cell-type specific 
apoptosis, these two activities must first be separated. All previous attempts at uncoupling 
nuclear export and multimerization have been unsuccessful. Therefore, it is the aim of this study 
to uncouple the nuclear export and multimerization activities of Apoptin through executing a 
novel point mutation to a conserved isoleucine residue, I37, in the nuclear export sequence.   
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Materials and Methods 
 
Creation of mutants.  PCR based site-directed mutagenesis was used to create an I37A point 
mutation within the NES in Apoptin.  To ligate the gene into the correct reading frame and 
ensure propoer orientation in the expression vector, an EcoR I site was introduced onto the N-
terminal primer and a BamHI site was introduced onto the C-terminal primer.  (ApI37A forward 
primer: 5’ TGCAGAGAGATCCGGATTGGTGCCGCTGGAATTACAATCACTCTA 3’; 
ApI37A  reverse primer: 5’ TAGAGTGATTGTAATTCCAGCGGCACCAATCCGGATCTCTCT 
GCA 3’. Ap forward primer: 5’GCGAATTCATGAACGCTCTCCAAGAAGATACTC 3’;  Ap 
reverse primer: 5; GCGGATCCTTACAGTCTTATACGCCTTTTTGCGG 3’)  The following 
PCR protocol was used:  95 °C, 4 min, 1x | [95 °C, 30 s] [55 °C, 30 s] [72 °C, 1.5 min], 30x | 72 
°C, 5 min, 1x | 10 °C, ∞.  PCR products were agarose gel electrophoresed using a TAE (0.04M 
Tris-HCl, 1 mM EDTA, 57.2µL glacial acetic acid) and 9% agarose gel.  The products were 
purified from the agarose gel using a Promega Wizard PCR Preps DNA Purification System (cat. 
#A7170). 
 
Mutant cloning.  PCR products were subcloned into Promega  pGEM-T Vector (cat. #A3600).  
DH5α E. coli cells were chemically transformed with the ligated T vector.  The cell cultures were 
screened via x-gal and IPTG selection.  Colonies were grown on ampicillin plates and select 
colonies were alkaline lysed (0.2N NaOH, 1% SDS).  Presence of the gene insert in the T-vector 
was verified by colony PCR.  The gene insert was isolated by restriction digest with EcoR I and 
BamH I and purified by Promega Wizard PCR Preps DNA Purification System (cat. #A7170).  
The gene insert was ligated into the Clontech pGBKT7 vector (cat #K1612-1) with a Promega 
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T4 DNA ligase (cat #M180A).  The Clontech pACT2 vector (cat #K1604-A) with wild type 
Apoptin insert was provided by D.W. Heilman.  The positive colonies were inoculated in either 
ampicillin or kanamycin.  Select positive colonies were alkaline lysed (resuspension solution:  50 
mM glucose, 25 mM Tris·HCl, 10 mM EDTA at pH 8.0; lysis solution:  0.2 N NaOH, 1% SDS; 
neutralization solution:  3 M K
+
, 5 M OAc
-
) and purified for plasmid DNA by a Promega 
Wizard
®
 Plus Midipreps DNA Purification System (cat #A7640).  Dideoxy DNA sequencing of 
the purified product was performed by MacrogenUSA with T7 primers for both strands of the T-
vector to confirm the I37A mutation. 
  
Yeast transformation and selection.  Y187 yeast were cultured in Clontech YPD Medium (cat. 
#630410).  The Y187 cells were cultured to a cell density with absorbance of 0.6.  50 mL of this 
culture was centrifuged and washed, after which the cells were resuspended in 100 mM LiAc.  
The Y187 were transformed with 240 µL PEG-4000, 36 µL 1.0M LiAc, 25 µL single-stranded 
carrier DNA (2.0 mg/mL), 50 µL of H2O and 2 µL of plasmid DNA:  pGBKT7/pACT2, 
pGBKT7-p53/pACT2-T (provided by D.W. Heilman), pGBKT7-ApWT/pACT2-ApWT, or 
pGBKT7-ApI37A/pACT2-ApWT.  The yeast were transformed for 30 minutes at 30˚C and then 
heat shocked at 42˚C for 20 minutes.  The transformed Y187 were plated onto selective media 
(Clontech Minimal SD Agar Base (cat. # 630412) and Clontech -Leu/-Trp DO Supplement (cat. 
# 630417)). 
 
Beta-galactosidase assay.  After three days of growth at 30 °C, colonies were lifted onto 3 mm 
Whatman filter paper and flash frozen in liquid nitrogen for 10 seconds.  The filter paper was 
13 
pressed to another Whatman filter paper that had been soaked in a 3.28 mg/mL x-gal, 0.0379M 
β-mercaptoethanol, 15.79  g/L Na2HPO4·7H2O, 5.40 g/L NaH2PO4·H2O, 0.75 g/L KCl, and 
0.264 g/L MgSO4·7H2O solution and incubated for 1.5 hours. 
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Results 
 
 
ApI37A site-directed mutagenesis.  In an effort to uncouple nuclear export from 
multimerization, a canonical isoleucine within the NES was mutated to an alanine (Figure 2A).  
I37 is among the conserved residues necessary to bind to Crm1, a major exportin.  Alanine is a 
small, inert amino acid which is expected to have no interaction with Crm1, which would likely 
eliminate nuclear export.  Previous studies have demonstrated that the N-terminal leucine 
residues in the NES were likely necessary for multimerization, as mutation of these resulted in 
elimination of both nuclear export and multimerization. A bipartite nuclear localization sequence 
is located on the N-terminal side of Apoptin, however this sequence will not be examined in this 
study.   
To execute the I37A mutation, PCR-based site-directed mutagenesis using the 
“megaprimer” technique was performed to construct half mutants.  Due to the location of NES, 
the mutant primers would create PCR products of different lengths.  As the PCR would only 
elongate to  the primer, truncated PCR products would be formed.  Screening the PCR products 
via agarose gel electrophoresis of Tax positive control demonstrated effective PCR and the 
negative control, which contained no DNA, ultimately showed no PCR product, indicating that 
there was likely no contamination of wild type Apoptin.  The first round of site-directed 
mutagenesis confirmed the creation of 0.1 kb and 0.2 kb half mutants (Figure 2B, lanes 3 and 4).  
Full-length ApI37A was assembled during the second round of site-directed mutagenesis.  Due to 
the fact that truncated PCR products have overlapping regions, they act as full-length templates 
for one another.  This would produce a PCR product of a full-sized Apoptin gene with the point 
mutation.  Gel electrophoresis confirmed the size of the full-length ApI37A (Figure 2C, lane 3).  
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This full-length product was purified in preparation for ligation into the expression vector.  
 
Cloning of ApI37A.  To determine protein-protein interaction the ApI37A mutant was inserted 
into pGBKT7, a component of a yeast 2-hybrid system.  Subcloning into T-vector was performed 
to increase the efficiency of restriction digest by EcoR I and BamH I, as using restriction 
enzymes on a PCR product are highly inefficient due to the terminal location of restriction sites.  
Ligation into the T vector was possible because the Taq polymerase used in PCR non-specifically 
adds adenosine bases to the end of a DNA sequence.  These overhanging adenosine bases base 
pair with the overhanging thymidine (T) residues in the vector, allowing for ligation.  To confirm 
that ApI37A was present in the T-vector a restriction digest of the ligated T-vector was performed 
and confirmed the presence of full-length Apoptin (Figure 2D).  To insure that the site-directed 
mutagenesis was successful in introducing the necessary point mutation, DNA sequencing was 
performed.  Sequencing in both directions on the ligated T-vector was necessary to ensure 
accuracy of the DNA sequence.  DNA sequencing confirmed the presence of the point mutation 
of I37A and retained homology with the rest of the gene (Figure 2E).   
A yeast 2-hybrid system was implemented to assess the degree of multimerization 
between ApWT and ApI37A.  The ApI37A that was excised from the T-vector by restriction 
enzymes EcoR I and BamH I was ligated into the pGBKT7 expression vector.  This vector also 
contains the TRP1 gene and the gene for the DNA-binding domain, half of a necessary 
transcription factor for the Gal4 promoter.  The primers used for mutagenesis were designed so 
that ApI37A was inserted in the correct reading frame for fusion to GAL DNA-binding domain.  
After cloning ApI37A into pGBKT7, a restriction digest of the ligated pGBK vector was 
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performed to ensure ApI37A was present in the positive clone.  The digest produced an excised 
fragment of approximately 0.4 kb, confirming the presence of ApI37A (Figure 2F). 
 
Transformation and expression of pGBKT7-ApI37A in Y187 yeast.  The second vector used 
in the yeast 2-hybrid system was a previously-constructed pACT2 into which ApWT was ligated.  
pACT2 contains the LEU2 gene as well as the gene for the transactivating domain, the second 
half of the Gal4 transcription factor, fused to Apoptin. The transactivating domain binds to RNA 
polymerase II for transcription initiation.  50 mL of 0.6 A of yeast were LiOAc transformed with 
pGBKT7 and pACT2 vectors.  To confirm that the Y187 yeast, which are deficient for Leu and 
Trp metabolism, were transformed with both plasmids, the yeast were plated onto -Leu/-Trp 
media for selection.  Yeast that were transformed in the 2-hybrid system would express the LEU2 
and TRP1 genes, introduced by pGBKT7 and pACT2, and grow in -Leu/-Trp media (Fig. 3, 
panels 1-5).  Untransformed controls did not grow on the -Leu/-Trp media, as expected (Fig. 3, -
C panel).  Yeast that had been transformed with both the pGBKT7 and pACT2 vectors in this 
assay were selected for the colony lift β-galactosidase assay because both halves of the Gal4 
transcription factor are required to assess the retention of multimerization. 
 
β-galactosidase assay.  When protein-protein interaction occurs, the DNA-binding domain from 
the pGBKT7 vector and the transactivating domain from the pACT2 are brought in proximity.  
The DNA-binding domain binds the Gal4 promoter and the transactivating domain recruits RNA 
polymerase II to the lacZ gene, which results in transcription of lacZ.  Transcription of the gene 
results in β -galactosidase production, which cleaves x-gal into galactose and 5-bromo-4-chloro-
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3-hydroxyindole (which stains the colonies blue).  To assess the degree of multimerization, a 
colony lift β-galactosidase assay was performed (Figure 4A).  Colonies were lifted to 3 mm 
Whatman paper, fractured in liquid nitrogen, and assayed for β-galactosidase activity.  The two 
positive controls, pGBKT7-p53/pACT2-T and pGBKT7-ApWT/pACT2-ApWT showed β-
galactosidase activity (Figure 4B, upper right and lower left), indicating protein-protein 
interaction.  These controls were selected because p53 and the SV40 Large-T antigen are known 
to interact with one another.  Similarly, wild-type Apoptin is well known to multimerize.In 
addition, pGBKT7-ApI37A/pACT2-ApWT also showed β-galactosidase activity (Figure 4B, 
lower right).    pGBKT7/pACT2 vectors demonstrated no β-galactosidase activity, as the two 
halves of the Gal4 promoter were not brought in proximity since Apoptin was not present in the 
vector and protein-protein interaction could not take place. (Figure 4B, upper left)
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Fig. 2 ApI37A site-directed mutagenesis and cloning into pGBKT7 vector.  ApI37A mutation 
was generated using the “megaprimer” method of PCR-based site-directed mutagenesis. Apoptin 
mutants were cloned into the pGBKT7 2-hybrid vector (a) A graphic representation of the 
Apoptin localization sequences indicating the canonical nuclear export sequence (NES) of 
Apoptin with the ApI37A mutant. (b)  Electrophoretic results of the first step of site-directed 
mutagenesis. Shown are Tax positive control (lane 1), negative control (lane 2), and ApI37A half 
mutants at 0.1 kb (lane 3) and 0.2 kb (lane 4). (c) Electrophoretic results of the second step of 
site-directed mutagenesis. Shown are Tax positive control (lane 1), negative control (lane 2), and 
ApI37A at 0.4 kb (lane 3). (d) Electrophoretic results of restriction digest of T-vector-ApI37A.  
One positive clone produced a band of approximately 0.4 kb, indicating the existence of ApI37A. 
(e) A portion of the chromatographic sequence analysis of the T-vector-ApI37A showing the 
successful I37A point mutation. (f) Electrophoretic results of the restriction digest of pGBKT7-
ApI37A.  Both positive clones produced a band of approximately 0.4 kb, indicating the existence 
of ApI37A. 
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Fig. 3 Transformation into Y187 S. cerevisiae and selection. pGBKT7-ApI37A mutants were 
cotransformed with pACT2-ApWT and positive clones were selected on -Leu/-Trp. 
ApWT/ApWT and p53/T pairs were also contransformed for use as controls. [1] 
pGBKT7/pACT2, [2] pGBKT7-ApI37Aa/pACT2-ApWT, [3] pGBKT7-ApI37Ab/pACT2-
ApWT, [4] pGBKT7-ApWT/pACT2-ApWT and [5] pGBKT7-p53/pACT2-T. 
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Fig. 4 2-hybrid β-galactosidase assay for protein-protein interaction. Positive yeast clones 
were cracked and stained with x-gal for 1 hour at 30°C. (a) A graphic representation of the β-
galactosidase  assay. Multimerization of ApI37A with ApWT will bring two halves of the 
required Gal4 transcription factor in proximity. This induces activation of lacZ, the product of 
which is β-galactosidase which will cleave x-gal into galactose and 5-bromo-4-chloro-3-
hydroxyindole. (b)  Negative control (upper left), positive controls (upper right & lower left), 
and ApI37A/ApWT (lower right) are shown.
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Discussion 
 
 
 Previous studies have shown that Apoptin multimerization and nuclear export are 
contained in overlapping domains.  This study has demonstrated, however, that uncoupling of 
these activities may be possible.  The nuclear export sequence of Apoptin follows a canonical 
nuclear export sequence.  Within the conserved NES, it is established that hydrophobic residues, 
leucine and isoleucine in particular, are essential for nuclear export.  These residues are 
responsible for recognition by Crm1, which in turn is responsible for nuclear export.  This study 
mutated a hydrophobic residue based on this canonical sequence.  Isoleucine 37 (I37) was 
determined to be one of these important amino acid residues for nuclear export as it was a 
conserved hydrophobic residue within the NES.  It was assumed that mutation of this residue 
would eliminate nuclear export.  As previous mutations of essential hydrophic residues L44 and 
L46 and the replacement of the NES with an analogous one resulted in concurrent loss of 
multimerization, it was not certain whether this point mutation would affect multimerization 
activity.  A yeast 2-hybrid system was used to determine if protein-protein interaction was still 
present.  This yeast 2-hybrid system involved fusion of the two halves of the GAL4 transcription 
factor to our mutant Apoptin and wild type Apoptin.  Multimerization of the ApI37A and ApWT 
brought the necessary transcription factor together, which resulted in transcription of the lacZ 
gene.  This resulted in β-galactosidase activity to visually demonstrate the presence of protein-
protein interaction.  
The ApI37A mutation, which is at the C-terminal side of the NES, retains multimerization 
activity.  This allows for a few theories as to how the multimerization and nuclear export 
activities share domains.  Previous simultaneous L44A and L46A mutations at the N-terminal 
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side of the NES resulted in loss of multimerization activity, as well as export.[9]  These results 
indicate that the multimerization domain may share residues only on the N-terminal end of the 
nuclear export sequence.  Alternatively, residues contributing to multimerization may be 
interspersed within the nuclear export sequence, including those residues not essential for 
nuclear export.  Point mutations, similar to the one performed in this study, of the entire nuclear 
export sequence will need to be performed to map which residues are shared by the two domains 
and which are exclusive to nuclear export.  If mutations to only N-terminal residues affect 
multimerization, the former theory will be proven.  However, if mutations to amino acids 
throughout the nuclear export affect multimerization, then the latter theory will be corroborated. 
As the two activities were previously coupled, loss of one activity resulted in loss of the 
other.  This made it difficult to determine which function was responsible for apoptosis or cell-
type specific selectivity.  Uncoupling the multimerization domain and nuclear export is important 
in determining what roles the two activities have in the induction of apoptosis and cell-type 
selectivity.  Previous data suggests that Apoptin is heavily multimerized in primary cells, but 
becomes more soluble in transformed cells.[unpublished data, D.W. Heilman]  This is theorized 
to affect cell-type specific subcellular localization of Apoptin.  Thus a differential cytoplasmic 
concentration of Apoptin is observed in primary and transformed cells.  If Apoptin is heavily 
multimerized in primary cells, there would be a small pool of Apoptin that can undergo nuclear 
localization.  If for transformed cells Apoptin is more soluble, then there is a larger mobile pool 
of Apoptin for nuclear localization.  This increased solubility results in greater nuclear 
localization.  It can be theorized that this change in multimerization is the regulatory mechanism 
responsible for the cell type selectivity in localization.  Furthermore, multimerization could 
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affect the activity of nuclear export simply in its location relative to the NES.  As 
multimerization activity and nuclear export activity share domains, multimerization of Apoptin 
could prevent Crm1 access to the nuclear export sequence.  If the nuclear export sequence is 
responsible for apoptotic interactions, the differential multimerization of Apoptin between cell 
types could explain cell type-selective apoptosis. 
The isolation of multimerization is important for determining what role differential 
multimierization has in cell-type specific apoptosis, assuming differential multimerization is not 
affected by eliminating nuclear export.  This would confirm the theory that transformed cells 
alter Apoptin multimerization activity.  The next theory to address is whether multimerization is 
responsible for apoptotic interaction.  If multimerization is responsible for apoptotic interaction, 
then cell-type specific apoptosis is dependent on multimerization alone, and that nuclear export 
activity is not required. 
Assuming differential multimerization is affected by the elimination of the NES, the 
theory that nuclear export activity is required for cell-type specific localization is confirmed.  
Next it must be determined whether nuclear export is also responsible for apoptotic interaction.  
If this theory is corroborated, then our Apoptin mutant would not be able to induce apoptosis.  
There is also the possibility that both domains are responsible for only one of the activities, 
differential aggregation and apoptosis.  In this case our mutant may retain differential 
multimerization but fail to induce apoptosis, or vice versa.  Additionally, there is the more 
complex scenario of both functions being required cell-type specific apoptosis.  For example, 
multimerization may be responsible for differential multimerization, and the NES is responsible 
24 
for induction of apoptosis.  However, it is possible that differential multimerization is a 
prerequisite to apoptotic interaction. 
Once nuclear export deficiency has been verified, the role of multimerization in cell type-
specific apoptosis can be elucidated.  The role of multimerization in cell specific apoptosis is 
vital to the design of a small synthetic analog.  If multimerization is required for apoptotic 
interaction, then Apoptin is interacting with its apoptotic target via a large protein area.  The 
synthetic drug would have to be designed to simulate this large protein interaction.  Essentially, 
this makes the drug extremely difficult to design.  On the other hand, if multimerization is not 
required for apoptotic interaction, then a single Apoptin molecule is responsible for apoptosis.  
This translates into small protein-protein interaction surface area, where only a few residues are 
required.  The drug would then only have to simulate a small interaction area.  This would 
simplify the design and manufacturing costs of this drug.  Therefore, the role of multimerization 
in the apoptotic interaction is important for the feasibility of developing a synthetic analog to 
mimic the mechanism of Apoptin cell-type specific apoptosis. 
 Though it can be reasonably assumed that the point mutation of the canonical amino acid 
residue within the NES will eliminate nuclear export activity, this will need to be verified.  To 
verify that these activities are uncoupled, fluorescence analysis to determine localization of 
ApI37A is required to determine if nucleocytoplasmic shuttling is preserved.  To insure that 
nuclear localization can only be affected by the nuclear export sequence, the NLS of Apoptin can 
be removed or mutated.  Apoptin can then be fused to a fluorescent tag such as GFP or HA, 
though because GFP is hypothesized to have abnormal effects on the subcellular localization of 
Apoptin, another fluorescent tag such as HA would be prefereable.  The data should show diffuse 
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localization of Apoptin if nuclear export activity was eliminated.  Otherwise, the data would 
show localization of Apoptin within the cytoplasm exclusively if nuclear export activity was 
retained. 
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